Yuwei Zhang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Yuwei Zhang has a total of 91 co-authors. Here are the top co-authors by number of shared publications:
Qing Shao
Department of Endocrinology and Metabolism, Laboratory of Diabetes and Metabolism Research, West China Hospital, Sichuan University
6 shared publicationsLiu Wang
Department of Endocrinology and Metabolism, West China Hospital, Sichuan University
5 shared publicationsLing Zhong
Department of Endocrinology and Metabolism West China Hospital, Sichuan University Chengdu Sichuan China
4 shared publicationsLanyu Gao
Department of Endocrinology and Metabolism, Laboratory of Diabetes and Metabolism Research, West China Hospital, Sichuan University
3 shared publicationsFei Chen
Department of Otolaryngology‐Head & Neck Surgery West China Hospital, Sichuan University Chengdu China
2 shared publicationsJibran Nehal Syed
Department of Translational Medicine, The Hospital for Sick Children, Toronto, ON, M5S 1A1, Canada
2 shared publications
Latest Publications
- 18 October 2026
- Published by Wiley in The Laryngoscope
Thyroid and Parathyroid Dysfunction Following Larynx‐Trachea‐Thyroid‐Parathyroid Allotransplantation
Larynx‐trachea‐thyroid‐parathyroid allotransplantation can restore essential laryngeal functions, but postoperative endocrine changes remain poorly understood. This study assessed thyroid and parathyroid function in four recipients. All developed early thyroid hormone alterations consistent with euthyroid sick syndrome, followed by variable endocrine outcomes. Two experienced thyrotoxicosis associated temporally with graft rejection, while another developed hypothyroidism and elevated parathyroid hormone during late rejection. Transient parathyroid hormone suppression was also observed. In contrast, the recipient without rejection maintained stable endocrine function. These findings suggest that endocrine changes may accompany graft rejection, although causality remains unestablished. Serial endocrine monitoring may complement conventional rejection surveillance but should not be used independently to diagnose rejection. Larger studies with longer follow‐up are needed to clarify the clinical significance of these findings.
- 18 October 2026
- Published by Wiley in The Laryngoscope
Thyroid and Parathyroid Dysfunction Following Larynx‐Trachea‐Thyroid‐Parathyroid Allotransplantation
Larynx‐trachea‐thyroid‐parathyroid allotransplantation can restore essential laryngeal functions, but postoperative endocrine changes remain poorly understood. This study assessed thyroid and parathyroid function in four recipients. All developed early thyroid hormone alterations consistent with euthyroid sick syndrome, followed by variable endocrine outcomes. Two experienced thyrotoxicosis associated temporally with graft rejection, while another developed hypothyroidism and elevated parathyroid hormone during late rejection. Transient parathyroid hormone suppression was also observed. In contrast, the recipient without rejection maintained stable endocrine function. These findings suggest that endocrine changes may accompany graft rejection, although causality remains unestablished. Serial endocrine monitoring may complement conventional rejection surveillance but should not be used independently to diagnose rejection. Larger studies with longer follow‐up are needed to clarify the clinical significance of these findings.
- Open Access
- 19 March 2026
- Published by Frontiers Media SA in Frontiers in Microbiology
- Vol. 17, 1783385
Impact of glucokinase activators on the gut microbiota of high-fat diet-induced obese and type 2 diabetic mice
Introduction: Glucokinase activators (GKAs) enhance glucose phosphorylation by activating glucokinase (GK) expressed in key metabolic organs (such as the liver, pancreas and intestine), thereby initiating cellular glucose metabolism and contributing to improved glycemic control. Among various GKAs under development, dorzagliatin and cadisegliatin (TTP399) are currently the most promising. The gut microbiota plays a critical role in the pathogenesis and progression of metabolic disorders, including obesity and type 2 diabetes. Substantial evidence indicates that long-term administration of oral glucose-lowering agents, such as metformin, can modulate the composition and function of the gut microbiota. Nevertheless, whether GKAs-as emerging oral hypoglycemic agents-also influence gut microbial homeostasis remains unexplored. This study aims to investigate the effects of oral GKAs on intestinal barrier integrity and gut microbiota composition in high-fat diet (HFD)-induced obese/type 2 diabetic mice. In addition, we compare the differential impacts of distinct GKA agents on glycemic regulation and gut microbial communities. Methods: Mice were randomly assigned to receive oral gavage of either a vehicle, dorzagliatin, or TTP399 for four consecutive weeks following 5 weeks of HFD feeding. Throughout the study, changes in key metabolic parameters, intestinal barrier integrity, and inflammatory markers were evaluated. Additionally, fecal samples were collected and subjected to 16S-rRNA gene sequencing for analysis of the gut microbiota composition. Results: Both dorzagliatin and TTP399 exerted beneficial hypoglycemic effects in HFD mice. Furthermore, results also showed that both dorzagliatin and TTP399 regulated the gut microbiota structure in HFD mice, specifically increasing the relative abundance of short-chain fatty acids-producing and anti-inflammatory bacteria. Notably, under the conditions of this study, neither activator exhibited significant effects on intestinal barrier integrity or inflammatory markers. Discussion: Dorzagliatin and TTP399 are associated with alterations in gut microbiota composition at the genus level in HFD-fed mice, with a concomitant increase in the abundance of beneficial genera, and no significant association with changes in intestinal barrier integrity or inflammation. Further investigation is warranted to elucidate the association between long-term GKAs treatment and microbial communities, as well as the potential relationship between microbial changes and hypoglycemic effects.
- 19 March 2026
- Published by Frontiers Media SA in Frontiers in Microbiology
- Vol. 17, 1783385
Open AccessImpact of glucokinase activators on the gut microbiota of high-fat diet-induced obese and type 2 diabetic mice
Introduction: Glucokinase activators (GKAs) enhance glucose phosphorylation by activating glucokinase (GK) expressed in key metabolic organs (such as the liver, pancreas and intestine), thereby initiating cellular glucose metabolism and contributing to improved glycemic control. Among various GKAs under development, dorzagliatin and cadisegliatin (TTP399) are currently the most promising. The gut microbiota plays a critical role in the pathogenesis and progression of metabolic disorders, including obesity and type 2 diabetes. Substantial evidence indicates that long-term administration of oral glucose-lowering agents, such as metformin, can modulate the composition and function of the gut microbiota. Nevertheless, whether GKAs-as emerging oral hypoglycemic agents-also influence gut microbial homeostasis remains unexplored. This study aims to investigate the effects of oral GKAs on intestinal barrier integrity and gut microbiota composition in high-fat diet (HFD)-induced obese/type 2 diabetic mice. In addition, we compare the differential impacts of distinct GKA agents on glycemic regulation and gut microbial communities. Methods: Mice were randomly assigned to receive oral gavage of either a vehicle, dorzagliatin, or TTP399 for four consecutive weeks following 5 weeks of HFD feeding. Throughout the study, changes in key metabolic parameters, intestinal barrier integrity, and inflammatory markers were evaluated. Additionally, fecal samples were collected and subjected to 16S-rRNA gene sequencing for analysis of the gut microbiota composition. Results: Both dorzagliatin and TTP399 exerted beneficial hypoglycemic effects in HFD mice. Furthermore, results also showed that both dorzagliatin and TTP399 regulated the gut microbiota structure in HFD mice, specifically increasing the relative abundance of short-chain fatty acids-producing and anti-inflammatory bacteria. Notably, under the conditions of this study, neither activator exhibited significant effects on intestinal barrier integrity or inflammatory markers. Discussion: Dorzagliatin and TTP399 are associated with alterations in gut microbiota composition at the genus level in HFD-fed mice, with a concomitant increase in the abundance of beneficial genera, and no significant association with changes in intestinal barrier integrity or inflammation. Further investigation is warranted to elucidate the association between long-term GKAs treatment and microbial communities, as well as the potential relationship between microbial changes and hypoglycemic effects.
- Open Access
- 19 March 2026
- Published by Frontiers Media SA in Frontiers in Endocrinology
- Vol. 17, 1786731
The dual role of urinary C-peptide/creatinine ratio: predicting insulin resistance in non-diabetic adults and microvascular complications risk in patients with type 2 diabetes
Background and purpose: Insulin resistance (IR) is a key driver of type 2 diabetes mellitus (T2DM) onset, and diabetic microvascular complications (DMC) represent its poor prognosis. However, simple and non-invasive screening methods for detection of IR and DMC are limited. The urinary C-peptide/creatinine ratio (UCPCR) can be used to measure β-cell function, and we aimed to evaluate its utility as a surrogate marker for IR in non-diabetic individuals and for DMC risk in patients with T2DM. Methods: This cross-sectional study enrolled 447 individuals (255 non-diabetic adults and 192 T2DM patients) from November 2023 to September 2025. The non-diabetic cohort was divided into IR and non-IR groups according to the Matsuda index. The diabetic cohort was divided into DMC and non-DMC groups. Fasting UCPCR (0hUCPCR) and 2-h post-OGTT/steamed bread meal (2hUCPCR) were measured. Multiple regression analysis was used to describe the association between UCPCR and the Matsuda index or DMC. Diagnostic accuracy was assessed using receiver operating characteristic (ROC) curve analysis. Results: In the non-diabetic individuals, both 0hUCPCR and 2hUCPCR were higher in the IR group, and they were negatively associated with the Matsuda index ( r = −0.488, r = −0.636) (all P < 0.001) by Spearman’s correlation analysis. Multiple linear regression analysis demonstrated that 0hUCPCR ( B = −0.351) and 2hUCPCR ( B = −0.162) were negatively associated with the Matsuda index (all P < 0.001). ROC analysis revealed that the areas under the curve (AUC) for screening IR were 0.780 and 0.831, with corresponding sensitivities of 64.4% and 77.6%, respectively. In the T2DM patients, 0hUCPCR and 2hUCPCR were lower in the DMC group, and they showed positive correlations with HOMA-β ( r = 0.582, r = 0.617) (all P < 0.001). Multivariable logistic regression analysis demonstrated that 2hUCPCR was negatively associated with DMC (OR = 0.627, P = 0.030). ROC analysis revealed that 2hUCPCR predicted DMC risk with an AUC of 0.751 and a sensitivity of 70.7%. Conclusion: Both 0hUCPCR and 2hUCPCR are promising markers for IR in non-diabetic adults, and 2hUCPCR is associated with lower risk of DMC in T2DM patients. Coupled with their practical advantages of simplicity and non-invasiveness, UCPCRs are promising tools for future large-scale screening in at-risk populations.
- 19 March 2026
- Published by Frontiers Media SA in Frontiers in Endocrinology
- Vol. 17, 1786731
Open AccessThe dual role of urinary C-peptide/creatinine ratio: predicting insulin resistance in non-diabetic adults and microvascular complications risk in patients with type 2 diabetes
Background and purpose: Insulin resistance (IR) is a key driver of type 2 diabetes mellitus (T2DM) onset, and diabetic microvascular complications (DMC) represent its poor prognosis. However, simple and non-invasive screening methods for detection of IR and DMC are limited. The urinary C-peptide/creatinine ratio (UCPCR) can be used to measure β-cell function, and we aimed to evaluate its utility as a surrogate marker for IR in non-diabetic individuals and for DMC risk in patients with T2DM. Methods: This cross-sectional study enrolled 447 individuals (255 non-diabetic adults and 192 T2DM patients) from November 2023 to September 2025. The non-diabetic cohort was divided into IR and non-IR groups according to the Matsuda index. The diabetic cohort was divided into DMC and non-DMC groups. Fasting UCPCR (0hUCPCR) and 2-h post-OGTT/steamed bread meal (2hUCPCR) were measured. Multiple regression analysis was used to describe the association between UCPCR and the Matsuda index or DMC. Diagnostic accuracy was assessed using receiver operating characteristic (ROC) curve analysis. Results: In the non-diabetic individuals, both 0hUCPCR and 2hUCPCR were higher in the IR group, and they were negatively associated with the Matsuda index ( r = −0.488, r = −0.636) (all P < 0.001) by Spearman’s correlation analysis. Multiple linear regression analysis demonstrated that 0hUCPCR ( B = −0.351) and 2hUCPCR ( B = −0.162) were negatively associated with the Matsuda index (all P < 0.001). ROC analysis revealed that the areas under the curve (AUC) for screening IR were 0.780 and 0.831, with corresponding sensitivities of 64.4% and 77.6%, respectively. In the T2DM patients, 0hUCPCR and 2hUCPCR were lower in the DMC group, and they showed positive correlations with HOMA-β ( r = 0.582, r = 0.617) (all P < 0.001). Multivariable logistic regression analysis demonstrated that 2hUCPCR was negatively associated with DMC (OR = 0.627, P = 0.030). ROC analysis revealed that 2hUCPCR predicted DMC risk with an AUC of 0.751 and a sensitivity of 70.7%. Conclusion: Both 0hUCPCR and 2hUCPCR are promising markers for IR in non-diabetic adults, and 2hUCPCR is associated with lower risk of DMC in T2DM patients. Coupled with their practical advantages of simplicity and non-invasiveness, UCPCRs are promising tools for future large-scale screening in at-risk populations.
- Open Access
- 27 October 2025
- Published by Ivyspring International Publisher in International Journal of Biological Sciences
- Vol. 21 (15) , 6978-6996
TGF-β1/SMAD3-mediated Non-canonical Hedgehog Signaling Promotes Pancreatic Stellate Cell Activation and Fibrosis in Chronic Pancreatitis
Excessive Hedgehog (Hh) signaling activity contributes to fibrosis in multiple organs. However, its role in pancreatic stellate cell (PSC) activation and fibrosis development during chronic pancreatitis (CP) remains elusive. We show that GLI2 is one of the top-ranked effectors in the pancreas of CP patients and is highly expressed in activated PSCs. PSC-specific deletion of Gli2, but not Smo, significantly reduces fibrosis and the severity of the mouse CP, indicating that GLI2 in PSCs can be driven by non-canonical fashion during CP. In culture-activated primary PSCs, early nuclear translocation and increased GLI2 expression are observed promptly following in vitro culture. Whereas GLI2 inhibition reduces PSC activation, SMO inhibition dose not consistently affect changes in GLI2 levels or PSC activation. TGF-β1 promotes GLI2 activation and expression, while these processes and resultant PSC activation are reversed by TGF-β1/SMAD3 inhibition. Altogether, these findings demonstrate the activation of the non-canonical Hh pathway in PSCs during CP and highlight that GLI2 represents a promising therapeutic target for CP.
- 27 October 2025
- Published by Ivyspring International Publisher in International Journal of Biological Sciences
- Vol. 21 (15) , 6978-6996
Open AccessTGF-β1/SMAD3-mediated Non-canonical Hedgehog Signaling Promotes Pancreatic Stellate Cell Activation and Fibrosis in Chronic Pancreatitis
Excessive Hedgehog (Hh) signaling activity contributes to fibrosis in multiple organs. However, its role in pancreatic stellate cell (PSC) activation and fibrosis development during chronic pancreatitis (CP) remains elusive. We show that GLI2 is one of the top-ranked effectors in the pancreas of CP patients and is highly expressed in activated PSCs. PSC-specific deletion of Gli2, but not Smo, significantly reduces fibrosis and the severity of the mouse CP, indicating that GLI2 in PSCs can be driven by non-canonical fashion during CP. In culture-activated primary PSCs, early nuclear translocation and increased GLI2 expression are observed promptly following in vitro culture. Whereas GLI2 inhibition reduces PSC activation, SMO inhibition dose not consistently affect changes in GLI2 levels or PSC activation. TGF-β1 promotes GLI2 activation and expression, while these processes and resultant PSC activation are reversed by TGF-β1/SMAD3 inhibition. Altogether, these findings demonstrate the activation of the non-canonical Hh pathway in PSCs during CP and highlight that GLI2 represents a promising therapeutic target for CP.
- 30 August 2025
- Published by Elsevier in Molecular Aspects of Medicine
- Vol. 105, 101397
Liver aging: underlying mechanisms and therapeutic strategies
- 30 August 2025
- Published by Elsevier in Molecular Aspects of Medicine
- Vol. 105, 101397
Liver aging: underlying mechanisms and therapeutic strategies
- 12 July 2025
- Published by Springer Nature in European Archives of Oto-Rhino-Laryngology
- p. 1-6
Thyroid function and viability after larynx-trachea-thyroid allotransplantation: a case series
Introduction Larynx-trachea-thyroid allotransplantation is a multi-organ cluster transplant that involves both solid organs and the thyroid gland. Thyroid dysfunction is frequently reported after an organ transplant. However, there are few reports neither about the thyroid function after laryngeal allotransplantation nor about the feasibility of thyroid allotransplantation. Methods We collected preoperative data and conducted follow-ups on three patients who underwent larynx-trachea-thyroid allotransplantation at the Department of Otolaryngology and Head and Neck Surgery in West China Hospital. Thyroid function and viability were evaluated perioperatively and after discharge using thyroid ultrasound, serological tests, and pathological examinations. Results The first patient experienced euthyroid sick syndrome (ESS) post-transplant, with persistently low levels of free triiodothyronine during follow-up. The second patient, who received a graft from a donor with Graves’ disease, developed thyrotoxicosis post-transplant, which was subsequently diagnosed as hyperthyroidism. Pathological examination revealed lymphocytic thyroiditis 9 months post-transplant. The third patient also developed ESS and subclinical hypothyroidism following the transplant. Thyroid ultrasound and biopsy were conducted on all patients, indicating good graft viability and no evidence of immunological rejection. Conclusion Thyroid dysfunction is frequent after larynx-trachea-thyroid allotransplantation and careful monitoring is critical. Thyroid allotransplantation is feasible and might be an alternative for special candidates.
- 12 July 2025
- Published by Springer Nature in European Archives of Oto-Rhino-Laryngology
- p. 1-6
Thyroid function and viability after larynx-trachea-thyroid allotransplantation: a case series
Introduction Larynx-trachea-thyroid allotransplantation is a multi-organ cluster transplant that involves both solid organs and the thyroid gland. Thyroid dysfunction is frequently reported after an organ transplant. However, there are few reports neither about the thyroid function after laryngeal allotransplantation nor about the feasibility of thyroid allotransplantation. Methods We collected preoperative data and conducted follow-ups on three patients who underwent larynx-trachea-thyroid allotransplantation at the Department of Otolaryngology and Head and Neck Surgery in West China Hospital. Thyroid function and viability were evaluated perioperatively and after discharge using thyroid ultrasound, serological tests, and pathological examinations. Results The first patient experienced euthyroid sick syndrome (ESS) post-transplant, with persistently low levels of free triiodothyronine during follow-up. The second patient, who received a graft from a donor with Graves’ disease, developed thyrotoxicosis post-transplant, which was subsequently diagnosed as hyperthyroidism. Pathological examination revealed lymphocytic thyroiditis 9 months post-transplant. The third patient also developed ESS and subclinical hypothyroidism following the transplant. Thyroid ultrasound and biopsy were conducted on all patients, indicating good graft viability and no evidence of immunological rejection. Conclusion Thyroid dysfunction is frequent after larynx-trachea-thyroid allotransplantation and careful monitoring is critical. Thyroid allotransplantation is feasible and might be an alternative for special candidates.
- Open Access
- 1 January 2025
- Published by Aging and Disease in Aging and disease
- Vol. 16 (6) , 3505-3519
Alpha-Glucosidase Inhibitors in Aging and Aging-Related Diseases: Clinical Applications and Relevant Mechanisms
Aging is a complex and universal process marked by gradual functional declines at the cellular and tissue levels, often leading to a range of aging-related diseases such as diabetes, cardiovascular diseases, and cancer. Delaying the aging process can help prevent, slow down, and alleviate the severity of these various conditions, enhancing overall health and well-being. Alpha-glucosidase inhibitors (AGIs) are a class of widely used antidiabetic drugs that inhibit alpha-glucosidase in the small intestinal mucosa, delaying carbohydrate absorption and reducing postprandial hyperglycemia. Beyond their roles in diabetes treatment, AGIs have shown potential in extending lifespan and effectively treating aging-related diseases by modulating oxidative stress, gut microbiota, inflammatory responses, and nutrient-sensing pathways. This review summarizes recent advancements in the application of AGIs for preventing and treating aging and aging-related diseases, with a focus on their mechanisms and roles in these processes.
- 1 January 2025
- Published by Aging and Disease in Aging and disease
- Vol. 16 (6) , 3505-3519
Open AccessAlpha-Glucosidase Inhibitors in Aging and Aging-Related Diseases: Clinical Applications and Relevant Mechanisms
Aging is a complex and universal process marked by gradual functional declines at the cellular and tissue levels, often leading to a range of aging-related diseases such as diabetes, cardiovascular diseases, and cancer. Delaying the aging process can help prevent, slow down, and alleviate the severity of these various conditions, enhancing overall health and well-being. Alpha-glucosidase inhibitors (AGIs) are a class of widely used antidiabetic drugs that inhibit alpha-glucosidase in the small intestinal mucosa, delaying carbohydrate absorption and reducing postprandial hyperglycemia. Beyond their roles in diabetes treatment, AGIs have shown potential in extending lifespan and effectively treating aging-related diseases by modulating oxidative stress, gut microbiota, inflammatory responses, and nutrient-sensing pathways. This review summarizes recent advancements in the application of AGIs for preventing and treating aging and aging-related diseases, with a focus on their mechanisms and roles in these processes.
- Open Access
- 22 November 2024
- Published by MDPI AG in Biomolecules
- Vol. 14 (12) , 1485
Hedgehog Signaling Pathway in Fibrosis and Targeted Therapies
Hedgehog (Hh) signaling is a well-established developmental pathway; it is crucial for early embryogenesis, cell differentiation, and damage-driven regeneration. It is being increasingly recognized that dysregulated Hh signaling is also involved in fibrotic diseases, which are characterized by excessive extracellular matrix deposition that compromises tissue architecture and function. As in-depth insights into the mechanisms of Hh signaling are obtained, its complex involvement in fibrosis is gradually being illuminated. Notably, some Hh-targeted inhibitors are currently under exploration in preclinical and clinical trials as a means to prevent fibrosis progression. In this review, we provide a concise overview of the biological mechanisms involved in Hh signaling. We summarize the latest advances in our understanding of the roles of Hh signaling in fibrogenesis across the liver, kidneys, airways, and lungs, as well as other tissues and organs, with an emphasis on both the shared features and, more critically, the distinct functional variations observed across these tissues and organs. We thus highlight the context dependence of Hh signaling, as well as discuss the current status and the challenges of Hh-targeted therapies for fibrosis.
- 22 November 2024
- Published by MDPI AG in Biomolecules
- Vol. 14 (12) , 1485
Open AccessHedgehog Signaling Pathway in Fibrosis and Targeted Therapies
Hedgehog (Hh) signaling is a well-established developmental pathway; it is crucial for early embryogenesis, cell differentiation, and damage-driven regeneration. It is being increasingly recognized that dysregulated Hh signaling is also involved in fibrotic diseases, which are characterized by excessive extracellular matrix deposition that compromises tissue architecture and function. As in-depth insights into the mechanisms of Hh signaling are obtained, its complex involvement in fibrosis is gradually being illuminated. Notably, some Hh-targeted inhibitors are currently under exploration in preclinical and clinical trials as a means to prevent fibrosis progression. In this review, we provide a concise overview of the biological mechanisms involved in Hh signaling. We summarize the latest advances in our understanding of the roles of Hh signaling in fibrogenesis across the liver, kidneys, airways, and lungs, as well as other tissues and organs, with an emphasis on both the shared features and, more critically, the distinct functional variations observed across these tissues and organs. We thus highlight the context dependence of Hh signaling, as well as discuss the current status and the challenges of Hh-targeted therapies for fibrosis.
- Open Access
- 30 July 2024
- Published by Frontiers Media SA in Frontiers in Public Health
- Vol. 12, 1438945
Point-of-care Testing HbA1c screening for type 2 diabetes in urban and rural areas of China: a cost-effectiveness analysis
Background: Point-of-care Testing (POCT) glycosylated hemoglobin (HbA1c) is a convenient, cheap, effective and accessible screening method for type 2 diabetes in rural areas and community settings that is widely used in the European region and Japan, but not yet widespread in China. The study is the first to evaluate the cost-effectiveness of POCT HbA1c, fasting capillary glucose (FCG), and venous blood HbA1c to screen for type 2 diabetes in urban and rural areas of China, and to identify the best socio-economically beneficial screening strategy.Methods: Based on urban and rural areas in China, economic models for type 2 diabetes screening were constructed from a social perspective. The subjects of this study were adults aged 18–80 years with undiagnosed type 2 diabetes. Three screening strategies were established for venous blood HbA1c, FCG and POCT HbA1c, and cost-effectiveness analysis was performed by Markov models. One-way sensitivity analysis and probabilistic sensitivity analysis were performed on all parameters of the model to verify the stability of the results.Results: Compared with FCG, POCT HbA1c was cost-effective with an incremental cost-utility ratio (ICUR) of $500.06/quality-adjusted life year (QALY) in urban areas and an ICUR of $185.10/QALY in rural areas, within the willingness-to-pay threshold (WTP = $37,653). POCT HbA1c was cost-effective with lower cost and higher utility compared with venous blood HbA1c in both urban and rural areas. In the comparison of venous blood HbA1c and FCG, venous blood HbA1c was cost-effective (ICUR = $20,833/QALY) in urban areas but not in rural areas (ICUR = $41,858/QALY). Sensitivity analyses showed that the results of the study were stable and credible.Conclusions: POCT HbA1c was cost-effective for type 2 diabetes screening in both urban and rural areas of China, which could be considered for future clinical practice in China. Factors such as geographic location, local financial situation and resident compliance needed to be considered when making the choice of venous blood HbA1c or FCG.
- 30 July 2024
- Published by Frontiers Media SA in Frontiers in Public Health
- Vol. 12, 1438945
Open AccessPoint-of-care Testing HbA1c screening for type 2 diabetes in urban and rural areas of China: a cost-effectiveness analysis
Background: Point-of-care Testing (POCT) glycosylated hemoglobin (HbA1c) is a convenient, cheap, effective and accessible screening method for type 2 diabetes in rural areas and community settings that is widely used in the European region and Japan, but not yet widespread in China. The study is the first to evaluate the cost-effectiveness of POCT HbA1c, fasting capillary glucose (FCG), and venous blood HbA1c to screen for type 2 diabetes in urban and rural areas of China, and to identify the best socio-economically beneficial screening strategy.Methods: Based on urban and rural areas in China, economic models for type 2 diabetes screening were constructed from a social perspective. The subjects of this study were adults aged 18–80 years with undiagnosed type 2 diabetes. Three screening strategies were established for venous blood HbA1c, FCG and POCT HbA1c, and cost-effectiveness analysis was performed by Markov models. One-way sensitivity analysis and probabilistic sensitivity analysis were performed on all parameters of the model to verify the stability of the results.Results: Compared with FCG, POCT HbA1c was cost-effective with an incremental cost-utility ratio (ICUR) of $500.06/quality-adjusted life year (QALY) in urban areas and an ICUR of $185.10/QALY in rural areas, within the willingness-to-pay threshold (WTP = $37,653). POCT HbA1c was cost-effective with lower cost and higher utility compared with venous blood HbA1c in both urban and rural areas. In the comparison of venous blood HbA1c and FCG, venous blood HbA1c was cost-effective (ICUR = $20,833/QALY) in urban areas but not in rural areas (ICUR = $41,858/QALY). Sensitivity analyses showed that the results of the study were stable and credible.Conclusions: POCT HbA1c was cost-effective for type 2 diabetes screening in both urban and rural areas of China, which could be considered for future clinical practice in China. Factors such as geographic location, local financial situation and resident compliance needed to be considered when making the choice of venous blood HbA1c or FCG.
- Open Access
- 26 February 2024
- Published by Frontiers Media SA in Frontiers in Microbiology
- Vol. 15, 1354989
Causal effect of gut microbiota of Defluviitaleaceae on the clinical pathway of “Influenza–Subacute Thyroiditis–Hypothyroidism”
Introduction: Hypothyroidism has been found to be influenced by gut microbiota. However, it remains unclear which a taxon of gut microbiota plays a key role in this function. Identifying the key bacteria affects hypothyroidism and through what mechanism will be helpful for the prevention of hypothyroidism through specific clinical pathways.Materials and methods: In Study A, 35 families and 130 genera of gut microbiota are used as exposures, with hypothyroidism as the outcome. The causal effect of the gut microbiota on hypothyroidism is estimated through two-sample Mendelian randomization. Combining the results of the two taxonomical levels, key taxa are selected, which in Study B are investigated for their causal association with multiple generally admitted causes of hypothyroidism and their more upstream factors. For validating and revealing the potential mechanism, enrichment analyses of the related genes and interacting transcription factors were performed.Results: In Study A, Defluviitaleaceae (OR: 0.043, 95% CI: 0.005–0.363, P = 0.018)/Defluviitaleaceae_UCG_011 (OR: 0.385, 95% CI: 0.172–0.865, P = 0.021) are significantly causally associated with hypothyroidism at both taxonomical levels. In Study B, Defluviitaleaceae family and Defluviitaleaceae_UCG_011 genus show the causal association with decreased thyroiditis (Family: OR: 0.174, 95% CI: 0.046–0.653, P = 0.029; Genus: OR: 0.139, 95% CI: 0.029–0.664, P = 0.043), decreased subacute thyroiditis (Family: OR: 0.028, 95% CI: 0.004–0.213, P = 0.007; Genus: OR: 0.018, 95% CI: 0.002–0.194, P = 0.013), decreased influenza (Family: OR: 0.818, 95% CI: 0.676–0.989, P = 0.038; Genus: OR: 0.792, 95% CI: 0.644–0.974, P = 0.027), and increased anti-influenza H3N2 IgG levels (Family: OR: 1.934, 95% CI: 1.123–3.332, P = 0.017; Genus: OR: 1.675, 95% CI: 0.953–2.943, P = 0.073). The results of the enrichment analysis are consistent with the findings and the suggested possible mechanisms.Conclusion: Defluviitaleaceae of the gut microbiota displays the probability of causally inhibiting the clinical pathway of “Influenza–Subacute Thyroiditis–Hypothyroidism” and acts as the potential probiotics to prevent influenza, subacute thyroiditis, and hypothyroidism.
- 26 February 2024
- Published by Frontiers Media SA in Frontiers in Microbiology
- Vol. 15, 1354989
Open AccessCausal effect of gut microbiota of Defluviitaleaceae on the clinical pathway of “Influenza–Subacute Thyroiditis–Hypothyroidism”
Introduction: Hypothyroidism has been found to be influenced by gut microbiota. However, it remains unclear which a taxon of gut microbiota plays a key role in this function. Identifying the key bacteria affects hypothyroidism and through what mechanism will be helpful for the prevention of hypothyroidism through specific clinical pathways.Materials and methods: In Study A, 35 families and 130 genera of gut microbiota are used as exposures, with hypothyroidism as the outcome. The causal effect of the gut microbiota on hypothyroidism is estimated through two-sample Mendelian randomization. Combining the results of the two taxonomical levels, key taxa are selected, which in Study B are investigated for their causal association with multiple generally admitted causes of hypothyroidism and their more upstream factors. For validating and revealing the potential mechanism, enrichment analyses of the related genes and interacting transcription factors were performed.Results: In Study A, Defluviitaleaceae (OR: 0.043, 95% CI: 0.005–0.363, P = 0.018)/Defluviitaleaceae_UCG_011 (OR: 0.385, 95% CI: 0.172–0.865, P = 0.021) are significantly causally associated with hypothyroidism at both taxonomical levels. In Study B, Defluviitaleaceae family and Defluviitaleaceae_UCG_011 genus show the causal association with decreased thyroiditis (Family: OR: 0.174, 95% CI: 0.046–0.653, P = 0.029; Genus: OR: 0.139, 95% CI: 0.029–0.664, P = 0.043), decreased subacute thyroiditis (Family: OR: 0.028, 95% CI: 0.004–0.213, P = 0.007; Genus: OR: 0.018, 95% CI: 0.002–0.194, P = 0.013), decreased influenza (Family: OR: 0.818, 95% CI: 0.676–0.989, P = 0.038; Genus: OR: 0.792, 95% CI: 0.644–0.974, P = 0.027), and increased anti-influenza H3N2 IgG levels (Family: OR: 1.934, 95% CI: 1.123–3.332, P = 0.017; Genus: OR: 1.675, 95% CI: 0.953–2.943, P = 0.073). The results of the enrichment analysis are consistent with the findings and the suggested possible mechanisms.Conclusion: Defluviitaleaceae of the gut microbiota displays the probability of causally inhibiting the clinical pathway of “Influenza–Subacute Thyroiditis–Hypothyroidism” and acts as the potential probiotics to prevent influenza, subacute thyroiditis, and hypothyroidism.